nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2020-7-3-94-101nodgo-631Research ArticleПРАКТИЧЕСКИЕ ВОПРОСЫ ДЕТСКОЙ ОНКОЛОГИИ-ГЕМАТОЛОГИИPRACTICAL QUESTIONS OF PEDIATRIC ONCOLOGY-HEMATOLOGYВеноокклюзионная болезнь печени при трансплантации гемопоэтических стволовых клеток и высокодозных режимах химиотерапии. Обзор литературыVeno-occlusive liver disease after hematopoietic stem cell transplantation and high-dose chemotherapy regimens. Literature reviewhttps://orcid.org/0000-0003-0179-2479КостареваА. О.KostarevaI. O.

Ирина Олеговна Костарева, врач-детский онколог отделения детской трансплантации костного мозга и гемопоэтических стволовых клеток НИИ детской онкологии и гематологии НМИЦ онкологии им. Н.Н. Блохина, младший научный сотрудник отдела оптимизации лечения и профилактики осложнений трансплантации гемопоэтических стволовых клеток НМИЦ ДГОИ им. Дмитрия Рогачева

115478, Москва, Каширское шоссе, 23, 

117997, Москва, ул. Саморы Машела, 1

Pediatric Oncologist Department of Pediatric Bone Marrow and Hematopoietic Stem Cell Transplantation of N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Researcher Department of Treatment Optimization and Prophylaxis of Hematopoietic Stem Cell Transplantation Associated Complications at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Health of Russia

23 Kashirskoe Shosse, Moscow, 115478, 

1 Samory Mashela St., Moscow, 11799

kostareva_92@mail.ruhttps://orcid.org/0000-0003-2395-4045МачневаЕ. Б.MachnevaE. B.

Кандидат медицинских наук, врач-гематолог отделения детской трансплантации костного мозга и гемопоэтических стволовых клеток НИИ детской онкологии и гематологии НМИЦ онкологии им. Н.Н. Блохина, врач-гематолог отделения детской трансплантации костного мозга Российской детской клинической больницы РНИМУ им. Н.И. Пирогова

115478, Москва, Каширское шоссе, 23, 

117997, Москва, Ленинский просп., 117

Cand. of Sci. (Med.), Hematologist Department of Pediatric Bone Marrow and Hematopoietic Stem Cell Transplantation of N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Hematologist Department of Bone Marrow Transplantation at the Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

23 Kashirskoe Shosse, Moscow, 115478, 

117 Leninskiy Prosp., Moscow, 117997

lena.machneva@yandex.ruhttps://orcid.org/0000-0003-3797-5808СидороваН. В.SidorovaN. V.

Заведующая отделением детской трансплантации костного мозга и гемопоэтических стволовых клеток НИИ детской онкологии и гематологии НМИЦ онкологии им. Н.Н. Блохина

115478, Москва, Каширское шоссе, 23

Head of the Department of Pediatric Bone Marrow and Hematopoietic Stem Cell Transplantation

23 Kashirskoe Shosse, Moscow, 115478

valerevna25@mail.ruhttps://orcid.org/0000-0002-2945-284XКиргизовК. И.KirgizovK. I.

Кандидат медицинских наук, заместитель директора по научной и образовательной работе НИИ детской онкологии и гематологии

115478, Москва, Каширское шоссе, 23

Cand. of Sci. (Med.), Deputy Director for Scientific and Educational Work of Research Institute of Pediatric Oncology and Hematology

23 Kashirskoe Shosse, Moscow, 115478

k.kirgizov@ronc.ruФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaRussian FederationФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; РДКБ ФГАОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian FederationФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of RussiaRussian Federation2020200920207394101Copyright © Костарева А.О., Мачнева Е.Б., Сидорова Н.В., Киргизов К.И., 20202020Костарева А.О., Мачнева Е.Б., Сидорова Н.В., Киргизов К.И.Kostareva I.O., Machneva E.B., Sidorova N.V., Kirgizov K.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/631

Веноокклюзионная болезнь печени (ВОБ), в настоящее время чаще обозначаемая термином «синдром синусоидальной обструкции» (ССО), представляет собой симптомокомплекс, развивающийся на ранних сроках после трансплантации гемопоэтических стволовых клеток и некоторых режимов химиотерапии вследствие токсичности ряда применяемых препаратов и сопровождающийся следующими симптомами: гипербилирубинемия, задержка жидкости, прибавка массы тела и болезненная гепатомегалия. По данным разных источников, частота встречаемости ССО/ВОБ у пациентов онкогематологического профиля составляет от 3 до 15 %. Несмотря на частоту развития данного осложнения, в настоящее время до конца не определены стандартные схемы его профилактики и терапии. В статье представлен краткий обзор литературы, демонстрирующий международный опыт в изучении и лечении ССО/ВОБ.

Veno-occlusive liver disease (VOD), now more often referred to as “sinusoidal obstruction syndrome” (SOS), is a symptom complex that develops in the early stages after hematopoietic stem cell transplantation and some chemotherapy regimens due to the toxicity of a number of drugs used and accompanied by the following symptoms: hyperbilirubinemia, fluid retention, weight gain, and painful hepatomegaly. According to various sources, the incidence of SOS/VOD in patients with oncohematological profile ranges from 3 to 15 %. At present, the standard schemes for the prevention of this condition are not fully recommended. The article presents a brief review of the literature, representing international experience in the study and treatment of SOS/VOD.

трансплантация гемопоэтических стволовых клетоквеноокклюзионная болезньдефибротидсиндром синусоидальной обструкцииhematopoietic stem cell transplantationveno-occlusive diseasedefibrotidesinusoidal obstruction syndromeReferencesFan C.Q., Crawford J.M. Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease). J Clin Exp Hepatol 2014;4(4):332–46. doi: 10.1016/j.jceh.2014.10.002.Fan C.Q., Crawford J.M. Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease). J Clin Exp Hepatol 2014;4(4):332–46. doi: 10.1016/j.jceh.2014.10.002.Shulman H.M., Fisher L.B., Schoch H.G., Henne K.W., McDonald G.B. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994;19(5):1171–81. PMID: 8175139.Shulman H.M., Fisher L.B., Schoch H.G., Henne K.W., McDonald G.B. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994;19(5):1171–81. PMID: 8175139.Carreras E., Bertz H., Arcese W., Vernant J.P., Tomás J.F., Hagglund H., Bandini G., Esperou H., Russell J., de la Rubia J., Di Girolamo G., Demuynck H., Hartmann O., Clausen J., Ruutu T., Leblond V., Iriondo A., Bosi A., Ben-Bassat I., Koza V., Apperley J.F. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. BloodCarreras E., Bertz H., Arcese W., Vernant J.P., Tomás J.F., Hagglund H., Bandini G., Esperou H., Russell J., de la Rubia J., Di Girolamo G., Demuynck H., Hartmann O., Clausen J., Ruutu T., Leblond V., Iriondo A., Bosi A., Ben-Bassat I., Koza V., Apperley J.F. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. BloodHo V.T., Revta C., Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2007;41(3):229–37. doi: 10.1038/sj.bmt.1705899.Ho V.T., Revta C., Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2007;41(3):229–37. doi: 10.1038/sj.bmt.1705899.Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin. EBMT Handbook 2019:315–22. doi: 10.1007/978-3-030-02278-5-42.Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin. EBMT Handbook 2019:315–22. doi: 10.1007/978-3-030-02278-5-42.Carreras E., Diaz-Ricart M. The role of the endothelium in the shortterm complications of hematopoietic SCT. Bone Marrow Transplant 2011;46(12):1495–502. doi: 10.1038/bmt.2011.65.Carreras E., Diaz-Ricart M. The role of the endothelium in the shortterm complications of hematopoietic SCT. Bone Marrow Transplant 2011;46(12):1495–502. doi: 10.1038/bmt.2011.65.Poisson J., Lemoinne S., Boulanger C., Durand F., Moreau R., Valla D., Rautou P.-E. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol 2017;66(1):212–27.Poisson J., Lemoinne S., Boulanger C., Durand F., Moreau R., Valla D., Rautou P.-E. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol 2017;66(1):212–27.Aird W.C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007;100(2):158–73. doi: 10.1161/01.RES.0000255691.76142.4a.Aird W.C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007;100(2):158–73. doi: 10.1161/01.RES.0000255691.76142.4a.Ruutu T., Carreras E. Hepatic Complications. In: Carreras E., Dufour C., Mohty M. (eds.). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Cham (CH): Springer, 2019. Chapter 49. doi: 10.1007/978-3-030-02278-5-49.Ruutu T., Carreras E. Hepatic Complications. In: Carreras E., Dufour C., Mohty M. (eds.). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Cham (CH): Springer, 2019. Chapter 49. doi: 10.1007/978-3-030-02278-5-49.Jones R.J., Lee K.S., Beschorner W.E., Vogel V.G., Grochow L.B., Braine H.G., Vogelsang G.B., Sensenbrenner L.L., Santos G.W., Saral R. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44(6):778–83. doi: 10.1097/00007890-198712000-00011.Jones R.J., Lee K.S., Beschorner W.E., Vogel V.G., Grochow L.B., Braine H.G., Vogelsang G.B., Sensenbrenner L.L., Santos G.W., Saral R. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44(6):778–83. doi: 10.1097/00007890-198712000-00011.Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol 2015;168(4):481–91. doi: 10.1111/bjh.13215.Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol 2015;168(4):481–91. doi: 10.1111/bjh.13215.Akil A., Zhang Q., Mumaw C.L., Raiker N., Yu J., Velez de Mendizabal N., Paczesny S. Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2015;21(10):1739–45. doi: 10.1016/j.bbmt.2015.07.004.Akil A., Zhang Q., Mumaw C.L., Raiker N., Yu J., Velez de Mendizabal N., Paczesny S. Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2015;21(10):1739–45. doi: 10.1016/j.bbmt.2015.07.004.Mohty M., Malard F., Abecassis M., Aerts E., Alaskar A.S., Aljurf M., Arat M., Bader P., Baron F., Bazarbachi A., Blaise D., Ciceri F., Corbacioglu S., Dalle J.H., Duarte R.F., Fukuda T., Huynh A., Masszi T., Michallet M., Nagler A., Carreras E. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2015;50(6):781–9. doi: 10.1038/bmt.2015.52.Mohty M., Malard F., Abecassis M., Aerts E., Alaskar A.S., Aljurf M., Arat M., Bader P., Baron F., Bazarbachi A., Blaise D., Ciceri F., Corbacioglu S., Dalle J.H., Duarte R.F., Fukuda T., Huynh A., Masszi T., Michallet M., Nagler A., Carreras E. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2015;50(6):781–9. doi: 10.1038/bmt.2015.52.Daly A., Savoie M.L., Geddes M., Chaudhry A., Stewart D., Duggan P., Bahlis N., Storek J., Brown C., Shafey M., Turner A.R., Russell J. Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities. Biol Blood Marrow Transplant 2012;18(12):1921–6. doi: 10.1016/j.bbmt.2012.07.017.Daly A., Savoie M.L., Geddes M., Chaudhry A., Stewart D., Duggan P., Bahlis N., Storek J., Brown C., Shafey M., Turner A.R., Russell J. Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities. Biol Blood Marrow Transplant 2012;18(12):1921–6. doi: 10.1016/j.bbmt.2012.07.017.Moscardó F., Urbano-Ispizua Á., Sanz G.F., Brunet S., Caballero D., Vallejo C., Sanz M.A. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003;31(6):545–50. doi: 10.1016/s0301-472x(03)00070-5.Moscardó F., Urbano-Ispizua Á., Sanz G.F., Brunet S., Caballero D., Vallejo C., Sanz M.A. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003;31(6):545–50. doi: 10.1016/s0301-472x(03)00070-5.Deeg H.J., Shulman H.M., Schmidt E., Yee G.C., Thomas E.D., Storb R. Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine. Transplant 1986;42(5):497–501. doi: 10.1097/00007890-198611000-00011.Deeg H.J., Shulman H.M., Schmidt E., Yee G.C., Thomas E.D., Storb R. Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine. Transplant 1986;42(5):497–501. doi: 10.1097/00007890-198611000-00011.Ha E., Mun K.C. Effects of cyclosporine on metalloproteinase in endothelial cells. Transplant Proc 2012;44(4):991–2. doi: 10.1016/j.transproceed.2012.03.015.Ha E., Mun K.C. Effects of cyclosporine on metalloproteinase in endothelial cells. Transplant Proc 2012;44(4):991–2. doi: 10.1016/j.transproceed.2012.03.015.Gooley T.A., Chien J.W., Pergam S.A., Hingorani S., Sorror M.L., Boeckh M., Martin P.J., Sandmaier B.M., Marr K.A., Appelbaum F.R., Storb R., McDonald G.B. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363(22):2091–101. doi: 10.1056/NEJMoa1004383.Gooley T.A., Chien J.W., Pergam S.A., Hingorani S., Sorror M.L., Boeckh M., Martin P.J., Sandmaier B.M., Marr K.A., Appelbaum F.R., Storb R., McDonald G.B. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363(22):2091–101. doi: 10.1056/NEJMoa1004383.Chalandon Y., Roosnek E., Mermillod B., Newton A., Ozsahin H., Wacker P., Helg C., Chapuis B. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004;10(5):347–54. doi: 10.1016/j.bbmt.2004.01.002/Chalandon Y., Roosnek E., Mermillod B., Newton A., Ozsahin H., Wacker P., Helg C., Chapuis B. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004;10(5):347–54. doi: 10.1016/j.bbmt.2004.01.002/Dignan F., Gujral D., Ethell M., Evans S., Treleaven J., Morgan G., Potter M. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from venoocclusive disease. Bone Marrow Transplant 2007;40(1):79–82. doi: 10.1038/sj.bmt.1705696.Dignan F., Gujral D., Ethell M., Evans S., Treleaven J., Morgan G., Potter M. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from venoocclusive disease. Bone Marrow Transplant 2007;40(1):79–82. doi: 10.1038/sj.bmt.1705696.Corbacioglu S., Cesaro S., Faraci M., Valteau-Couanet D., Gruhn B., Rovelli A., Boelens J.J., Hewitt A., Schrum J., Schulz A.S., Müller I., Stein J., Wynn R., Greil J., Sykora K.W., Matthes-Martin S., Führer M., O’Meara A., Toporski J., Sedlacek P., Dini G. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012;379(9823):1301–9. doi: 10.1016/S0140-6736(11)61938-7.Corbacioglu S., Cesaro S., Faraci M., Valteau-Couanet D., Gruhn B., Rovelli A., Boelens J.J., Hewitt A., Schrum J., Schulz A.S., Müller I., Stein J., Wynn R., Greil J., Sykora K.W., Matthes-Martin S., Führer M., O’Meara A., Toporski J., Sedlacek P., Dini G. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012;379(9823):1301–9. doi: 10.1016/S0140-6736(11)61938-7.Penack O., Socié G., van den Brink M.R. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood 2011;117(16):4181–9. doi: 10.1182/blood-2010-10-312934.Penack O., Socié G., van den Brink M.R. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood 2011;117(16):4181–9. doi: 10.1182/blood-2010-10-312934.Dignan F.L., Wynn R.F., Hadzic N., Karani J., Quaglia A., Pagliuca A., Veys P., Potter M.N.; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013;163(4):444–57. doi: 10.1111/bjh.12558.Dignan F.L., Wynn R.F., Hadzic N., Karani J., Quaglia A., Pagliuca A., Veys P., Potter M.N.; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013;163(4):444–57. doi: 10.1111/bjh.12558.Al Beihany A., Al Omar H., Sahovic E., Chaudhri N., Al Mohareb F., Al Sharif F., Al Zahrani H., Al Shanqeeti A., Seth P., Zaidi S., Morshed M., Al Anazi K., Mohamed G., Gyger M., Aljurf M. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant 2008;41(3):287–91. doi: 10.1038/sj.bmt.1705896.Al Beihany A., Al Omar H., Sahovic E., Chaudhri N., Al Mohareb F., Al Sharif F., Al Zahrani H., Al Shanqeeti A., Seth P., Zaidi S., Morshed M., Al Anazi K., Mohamed G., Gyger M., Aljurf M. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant 2008;41(3):287–91. doi: 10.1038/sj.bmt.1705896.Palomo M., Diaz-Ricart M., Rovira M., Escolar G., Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biology Blood Marrow Transplant 2011;17(4):497–506. doi: 10.1016/j.bbmt.2010.11.019.Palomo M., Diaz-Ricart M., Rovira M., Escolar G., Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biology Blood Marrow Transplant 2011;17(4):497–506. doi: 10.1016/j.bbmt.2010.11.019.Richardson P.G., Ho V.T., Cutler C., Glotzbecker B., Antin J.H., Soiffer R. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant 2013;19(1 Suppl):88–90. doi: 10.1016/j.bbmt.2012.10.023.Richardson P.G., Ho V.T., Cutler C., Glotzbecker B., Antin J.H., Soiffer R. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant 2013;19(1 Suppl):88–90. doi: 10.1016/j.bbmt.2012.10.023.Bonifazi F., Barbato F., Ravaioli F., Sessa M., Defrancesco I., Arpinati M., Cavo M., Colecchia A. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:489. doi: 10.3389/fimmu.2020.00489.Bonifazi F., Barbato F., Ravaioli F., Sessa M., Defrancesco I., Arpinati M., Cavo M., Colecchia A. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:489. doi: 10.3389/fimmu.2020.00489.Richardson P.G., Riches M.L., Kernan N.A., Brochstein J.A., Mineishi S., Termuhlen A.M., Arai S., Grupp S.A., Guinan E.C., Martin P.L., Steinbach G., Krishnan A., Nemecek E.R., Giralt S., Rodriguez T., Duerst R., Doyle J., Antin J.H., Smith A., Lehmann L., Champlin R., Gillio A., Bajwa R., D’Agostino R.B., Massaro J., Warren D., Miloslavsky M., Hume R.L., Iacobelli M., Nejadnik B., Hannah A.L., Soiffer R.J. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 2016;127(13):1656–65. doi: 10.1182/blood-2015-10-676924.Richardson P.G., Riches M.L., Kernan N.A., Brochstein J.A., Mineishi S., Termuhlen A.M., Arai S., Grupp S.A., Guinan E.C., Martin P.L., Steinbach G., Krishnan A., Nemecek E.R., Giralt S., Rodriguez T., Duerst R., Doyle J., Antin J.H., Smith A., Lehmann L., Champlin R., Gillio A., Bajwa R., D’Agostino R.B., Massaro J., Warren D., Miloslavsky M., Hume R.L., Iacobelli M., Nejadnik B., Hannah A.L., Soiffer R.J. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 2016;127(13):1656–65. doi: 10.1182/blood-2015-10-676924.Chalandon Y., Simonetta F., Dantin C., Koutsi A., Mamez A.-C., Beauverd Y., Tsopra O., Simon A., Bex S., Stephan C., Rodriguez Morales J.F., Polchlopek K., Ansari M., Tirefort Y., Roosnek E., Masouridi-Levrat S.; Efficient Prophylaxis with Defibrotide for Sinusoidal Obstruction Syndrome (SOS) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 2016;128(22):2204. doi: 10.1182/blood.V128.22.2204.2204.Chalandon Y., Simonetta F., Dantin C., Koutsi A., Mamez A.-C., Beauverd Y., Tsopra O., Simon A., Bex S., Stephan C., Rodriguez Morales J.F., Polchlopek K., Ansari M., Tirefort Y., Roosnek E., Masouridi-Levrat S.; Efficient Prophylaxis with Defibrotide for Sinusoidal Obstruction Syndrome (SOS) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 2016;128(22):2204. doi: 10.1182/blood.V128.22.2204.2204.Haussmann U., Fischer J., Eber S., Scherer F., Seger R., Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006;91(6):795– 800. PMID: 16769582.Haussmann U., Fischer J., Eber S., Scherer F., Seger R., Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006;91(6):795– 800. PMID: 16769582.Corbacioglu S., Kernan N., Lehmann L., Brochstein J., Revta C., Grupp S., Martin P., Richardson P.G. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol 2012;5(3):291–302. doi: 10.1586/ehm.12.18.Corbacioglu S., Kernan N., Lehmann L., Brochstein J., Revta C., Grupp S., Martin P., Richardson P.G. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol 2012;5(3):291–302. doi: 10.1586/ehm.12.18.Richardson P.G., Soiffer R.J., Antin J.H., Uno H., Jin Z., Kurtzberg J., Martin P.L., Steinbach G., Murray K.F., Vogelsang G.B., Chen A.R., Krishnan A., Kernan N.A., Avigan D.E., Spitzer T.R., Shulman H.M., Di Salvo D.N., Revta C., Warren D., Momtaz P., Bradwin G., Wei L.J., Iacobelli M., McDonald G.B., Guinan E.C. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010;16(7):1005–17. doi: 10.1016/j.bbmt.2010.02.009.Richardson P.G., Soiffer R.J., Antin J.H., Uno H., Jin Z., Kurtzberg J., Martin P.L., Steinbach G., Murray K.F., Vogelsang G.B., Chen A.R., Krishnan A., Kernan N.A., Avigan D.E., Spitzer T.R., Shulman H.M., Di Salvo D.N., Revta C., Warren D., Momtaz P., Bradwin G., Wei L.J., Iacobelli M., McDonald G.B., Guinan E.C. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010;16(7):1005–17. doi: 10.1016/j.bbmt.2010.02.009.Schlegel P.G., Haber H.P., Beck J., Krümpelmann S., Handgretinger R., Bader P., Klingebiel T. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin. Ann Hematol 1998;76(1):37–41. doi: 10.1007/s002770050358.Schlegel P.G., Haber H.P., Beck J., Krümpelmann S., Handgretinger R., Bader P., Klingebiel T. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin. Ann Hematol 1998;76(1):37–41. doi: 10.1007/s002770050358.Mohty M., Malard F., Abecassis M., Aerts E., Alaskar A.S., Aljurf M., Arat M., Bader P., Baron F., Bazarbachi A., Blaise D., Ciceri F., Corbacioglu S., Dalle J.H., Dignan F., Fukuda T., Huynh A., Masszi T., Michallet M., Nagler A., Carreras E. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2016;51(7):906–12. doi: 10.1038/bmt.2016.130.Mohty M., Malard F., Abecassis M., Aerts E., Alaskar A.S., Aljurf M., Arat M., Bader P., Baron F., Bazarbachi A., Blaise D., Ciceri F., Corbacioglu S., Dalle J.H., Dignan F., Fukuda T., Huynh A., Masszi T., Michallet M., Nagler A., Carreras E. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2016;51(7):906–12. doi: 10.1038/bmt.2016.130.

The authors declare that there are no conflicts of interest present.